Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressive BCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to some targeted therapies for which dominant mechanisms of resistance have been observed, such as BCR-ABL mutations that cause resistance to imatinib in chronic myeloid leukemia,22 KRASG12C-mutant cancers appear to evolve diverse mechanisms of resistance to adagrasib.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [22]
Citations
Cites
Thompson, J. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.4876 · Cited by 38,993
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationThe Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Cited by
Items 101–200 of 1,008
Joseph, J. D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E. C., Chen, I., Darimont, B., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0226 · Cited by 578
Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 589
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Levine, R. L., Pardanani, A., Tefferi, A., & Gilliland, D. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2210 · Cited by 588
Bellodi, C., Lidonnici, M. R., Hamilton, A., Helgason, G. V., Soliera, A. R., Ronchetti, M., Galavotti, S., Young, K. W., Selmi, T., Yacobi, R., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35660 · Cited by 570
Rescuing the function of mutant p53
Bullock, A. N., & Fersht, A. R. (2001) · Nature Reviews Cancer · doi:10.1038/35094077 · Cited by 568
“Indeed, in clinical trials, some resistance to STI-571 occurs after initial remission as cells acquire further amplification of the BCR–ABL gene or mutations that disrupt the drug-binding sit”
BackgroundThomas, D. A. (2004) · Blood · doi:10.1182/blood-2003-08-2958 · Cited by 571
“[47, 19-73] [44, 16-79] [42, 19-75] Performance, ECOG”
Management of malignant gastrointestinal stromal tumours
Joensuu, H., Fletcher, C., Dimitrijevic, S., Silberman, S., Roberts, P., & Demetri, G. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00899-9 · Cited by 567
Receptor tyrosine kinases: mechanisms of activation and signaling
Hubbard, S. R., & Miller, W. T. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.010 · Cited by 531
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
“, and imatinib, in which resistance was observed in CML patients with mutations in the Bcr–Abl fusion protei”
BackgroundInhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W. H., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 554
Self-citationInhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome
Tang, J. Y., Mackay-Wiggan, J. M., Aszterbaum, M., Yauch, R. L., Lindgren, J., Chang, K., Coppola, C., Chanana, A. M., Marji, J., Bickers, D. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113538 · Cited by 547
de Lavallade, H., Apperley, J. F., Khorashad, J. S., Milojkovic, D., Reid, A. G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8154 · Cited by 551
Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D. S., Sawyers, C. L., Arber, D. A., Slovak, M. L., & Forman, S. J. (2003) · Blood · doi:10.1182/blood-2002-09-2780 · Cited by 547
Self-citationMDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
Mahon, F.-X., Belloc, F., Lagarde, V., Chollet, C., Moreau-Gaudry, F., Reiffers, J., Goldman, J. M., & Melo, J. V. (2003) · Blood · doi:10.1182/blood.v101.6.2368 · Cited by 538
G ENETICS OF M YELOID L EUKEMIAS
Kelly, L. M., & Gilliland, D. G. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.032802.115046 · Cited by 523
Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536759100 · Cited by 531
Albertson, D. G. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.06.007 · Cited by 527
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
“Relapse coincided with point mutations in the bcr-abl kinase domain in about half the relapsed patients, and in a third of patients, relapse could be ascribed to bcr-abl gene amplification and kinase overexpression (Gorre et al., 2001; Hochhaus et al., 2001; Shah et al., 2001).”
BackgroundElevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508
“Similarly, increased expression of the BCR-ABL kinase, frequently as a result of specific gene amplification, in imatinib-resistant cases of CML may contribute to resistance through a similar drug titration mechanism ( 13 ).”
BackgroundHehlmann, R., Hochhaus, A., & Baccarani, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61165-9 · Cited by 501
Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Laı̈, J.-L., Philippe, N., Facon, T., Fenaux, P., & Preudhomme, C. (2002) · Blood · doi:10.1182/blood.v100.3.1014 · Cited by 515
Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., Iacobucci, I., Amabile, M., Abruzzese, E., Orlandi, E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1516 · Cited by 511
Costa, D. B., Halmos, B., Kumar, A., Schumer, S. T., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 499
“and often in GIST [53,54].”
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507
Circumventing cancer drug resistance in the era of personalized medicine
Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503
“BCR-ABL amplification has been detected both in vitro and in imatinib-resistant CML specimens (26).”
BackgroundRational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Response and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
“One of the critical observations in clinical isolates from patients at the time of resistance was that BCR-ABL1 tyrosine kinase activity was frequently restored as assessed by levels of phosphorylation of the adapter protein CRKL (Gorre et al., 2001).”
BackgroundInfluentialAMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A., & Griffin, J. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603170 · Cited by 484
“…0007 – 0920/06 $30.00 www.bjcancer.com Resistance frequently results from the emergence of point mutations within the kinase domain of the BCR-ABL protein that reduce the binding affinity of imatinib, although it is occasionally associated with amplification of the BCR-ABL gene (Gorre et al, 2001).”
BackgroundInfluentialDebiec-Rychter, M., Cools, J., Dumez, H., Sciot, R., Stul, M., Mentens, N., Vranckx, H., Wasag, B., Prenen, H., Roesel, J., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.020 · Cited by 494
Brock, A., Chang, H., & Huang, S. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2556 · Cited by 486
“Numerous genetic mutations in BCR–ABL render the drug ineffectiv”
BackgroundmTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
Easton, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 459
“Activation of the tyrosine kinase fusion product BCR-ABL is absolutely required for the development of this type of leukemia, and molecularly defines this disease.”
BackgroundInfluentialvon Bubnoff, N., Schneller, F., Peschel, C., & Duyster, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07679-1 · Cited by 464
ALK in Lung Cancer: Past, Present, and Future
Shaw, A. T., & Engelman, J. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5353 · Cited by 461
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen, M. H., Williams, G., Johnson, J. R., Duan, J. Z., Gobburu, J. V. S., Rahman, A., Benson, K. A., Leighton, J. K., Kim, S. K., Wood, R., et al. (2002) · PubMed · Cited by 462
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 440
“Three clinically approved drugs target this tyrosine kinase, and each of these drugs is sensitive to an overlapping but distinct set of Bcr-Abl resistance mutation”
Targeting cancer with kinase inhibitors
Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76094 · Cited by 444
Cancer as a robust system: implications for anticancer therapy
Kitano, H. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1300 · Cited by 456
Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia
Johansson, B., Fioretos, T., & Mitelman, F. (2002) · Acta Haematologica · doi:10.1159/000046636 · Cited by 454
“Summarizing the secondary abnormalities in IFN-treated CML cases (table 3 ), it becomes clear that the incidences of p8, pPh, i(17q), p19, p21, and p17 are lower in the IFN-treated group compared to patients treated with Bu and/or Hy. Furthermore, and similar to the post-BMT group, the frequencies of secondary balance…”
ResultHeinrich, M. C., Rubin, B. P., Longley, B. J., & Fletcher, J. A. (2002) · Human Pathology · doi:10.1053/hupa.2002.124124 · Cited by 455
White, D. L., Saunders, V. A., Dang, P., Engler, J., Zannettino, A. C. W., Cambareri, A. C., Quinn, S. R., Manley, P. W., & Hughes, T. P. (2006) · Blood · doi:10.1182/blood-2005-11-4687 · Cited by 435
Ma, Y., Zeng, S., Metcalfe, D. D., Akin, C., Dimitrijevic, S., Butterfield, J. H., McMahon, G., & Longley, B. J. (2002) · Blood · doi:10.1182/blood.v99.5.1741 · Cited by 449
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Hamilton, A., Helgason, G. V., Schemionek, M., Zhang, B., Myssina, S., Allan, E. K., Nicolini, F. E., Müller-Tidow, C., Bhatia, R., Brunton, V. G., et al. (2012) · Blood · doi:10.1182/blood-2010-12-326843 · Cited by 435
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
Gerlinger, M., & Swanton, C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605912 · Cited by 421
“The emergence of a subclone of leukaemic cells carrying an imatinib resistance mutation in the BCR –ABL kinase domain is the main cause of relapse in patients treated with imatinib (Gorre et al, 2001).”
Tumour heterogeneity and the evolution of polyclonal drug resistance
Burrell, R. A., & Swanton, C. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.005 · Cited by 417
Blombery, P., Anderson, M. A., Gong, J.-N., Thijssen, R., Birkinshaw, R. W., Thompson, E. R., Teh, C. E., Nguyen, T., Xu, Z., Flensburg, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1119 · Cited by 434
“mutations in BCR-ABL1(21) and BTK(22)).”
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430
“Development of resistance to targeted therapies is a general phenomenon and is also seen in BCR-ABLtranslocated chronic myelogenous leukemias (CML) treated with imatinib (Gorre et al., 2001), BRAF mutant melanomas treated with the BRAF inhibitor vemurafenib (Chapman et al.”
Evolutionary Determinants of Cancer
Greaves, M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0439 · Cited by 395
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., & Miyamoto, M. (2003) · PubMed · Cited by 425
Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
Awad, M. M., Katayama, R., McTigue, M., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215530 · Cited by 416
Zhu, C., Mills, K. D., Ferguson, D. O., Lee, C., Manis, J., Fleming, J., Gao, Y., Morton, C. C., & Alt, F. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00770-5 · Cited by 421
Kinase mutations in human disease: interpreting genotype–phenotype relationships
Lahiry, P., Torkamani, A., Schork, N. J., & Hegele, R. A. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2707 · Cited by 420
“The demonstration that other fusion genes involving kinases underlie leukaemia suggested a more general association, and has led to the development of TK inhibition using agents such as imatini”
Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells
Ma, Y., Zhang, J., Yin, W., Zhang, Z., Song, Y., & Chang, X. (2016) · Nature Methods · doi:10.1038/nmeth.4027 · Cited by 418
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1486 · Cited by 411
“…steric hindrance has been invoked to explain the resistance of BCR-ABL-T315I, KIT-T670I, PDGFRA-T674I and EGFR-T790M to kinase inhibitor binding12,13,15,17, our data suggest that threonine mutation acts as well to promote the assembly of an enzymatically active kinase conformation by stabilizing…”
The developing cancer stem-cell model: clinical challenges and opportunities
Vermeulen, L., de Sousa e Melo, F., Richel, D. J., & Medema, J. P. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70257-1 · Cited by 393
Jänne, P. A., Engelman, J. A., & Johnson, B. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.985 · Cited by 405
Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30890 · Cited by 418
Self-citationHu, Y., Liu, Y., Pelletier, S., Buchdunger, E., Warmuth, M., Fabbro, D., Hallek, M., Van Etten, R. A., & Li, S. (2004) · Nature Genetics · doi:10.1038/ng1343 · Cited by 405
The BCR-ABL Story: Bench to Bedside and Back
Wong, S., & Witte, O. N. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104753 · Cited by 399
Golas, J. M., Arndt, K. T., Etienne, C., Lucas, J., Nardin, D., Gibbons, J. J., Frost, P., Ye, F., Boschelli, D. H., & Boschelli, F. (2003) · PubMed · Cited by 457
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 455
Drug resistance in cancer: Principles of emergence and prevention
Komarova, N. L., & Wodarz, D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501870102 · Cited by 414
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Chronic myeloid leukemia: mechanisms of blastic transformation
Perrotti, D., Jamieson, C., Goldman, J., & Skorski, T. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41246 · Cited by 397
Gajiwala, K. S., Wu, J. C., Christensen, J., Deshmukh, G. D., Diehl, W., DiNitto, J. P., English, J. M., Greig, M. J., He, Y.-A., Jacques, S. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812413106 · Cited by 391
“mutant (T670I) observed in patients with GIST corresponds to that found in Bcr-Abl that confers resistance to imatinib in chronic myelogenous leukemia patients (10, 13, 14).”
BackgroundRecurrent SETBP1 mutations in atypical chronic myeloid leukemia
Piazza, R., Valletta, S., Winkelmann, N., Redaelli, S., Spinelli, R., Pirola, A., Antolini, L., Mologni, L., Donadoni, C., Papaemmanuil, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2495 · Cited by 403
“Several groups have characterized mutations in leukemic cells from patients who had developed resistance to imatinib (65).”
BackgroundApperley, J. F. (2015) · The Lancet · doi:10.1016/s0140-6736(13)62120-0 · Cited by 381
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
“Gatekeeper and other mutational hot spots have been identified in variants of Gleevec-resistant BCR-AB”
BackgroundKinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H., Sun, Y., Ouyang, X., Gerald, W. L., Cordon-Cardo, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34764 · Cited by 391
Bradeen, H. A., Eide, C. A., O'Hare, T., Johnson, K. J., Willis, S. G., Lee, F. Y., Druker, B. J., & Deininger, M. W. (2006) · Blood · doi:10.1182/blood-2006-02-004580 · Cited by 393
Quintás-Cardama, A., Kantarjian, H., O'Brien, S., Borthakur, G., Bruzzi, J., Munden, R., & Cortes, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0329 · Cited by 388
Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O'Brien, S., Zhou, X., Luthra, R., Garcia-Manero, G., Giles, F., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404318 · Cited by 386
The Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in Cancer
Alves-Fernandes, D. K., & Jasiulionis, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133153 · Cited by 385
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
Adrián, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio760 · Cited by 381
“Although treatment with imatinib during the chronic phase of CML usually results in a durable response, treatment during the accelerated or blast phase typically fails owing to the emergence of resistance mutations in the BCR-ABL gen”
BackgroundKantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., Hochhaus, A., Radich, J. P., Saglio, G., et al. (2011) · Blood · doi:10.1182/blood-2010-03-277152 · Cited by 380
“Median duration of CML, mo (range) 58 (5-275) Median duration of prior imatinib therapy, mo (range) 32 ( 1 to 94)”
BackgroundTargeting multiple signal transduction pathways through inhibition of Hsp90
Zhang, H., & Burrows, F. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0549-9 · Cited by 377
“Furthermore, some mutations enhanced the oncogenic potency of Bcr-abl, causing a more aggressive form of the disease [22].”
BackgroundPuttini, M., Coluccia, A. M. L., Boschelli, F., Cleris, L., Marchesi, E., Donella-Deana, A., Ahmed, S., Redaelli, S., Piazza, R., Magistroni, V., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1199 · Cited by 375
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Del Re, M., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 356
Lee, J. C., Vivanco, I., Beroukhim, R., Huang, J. H. Y., Feng, W. L., DeBiasi, R. M., Yoshimoto, K., King, J. C., Nghiemphu, P., Yuza, Y., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030485 · Cited by 367
“To define which fraction of the EGFR pool represented the mutant allele in gliomas with EGFR missense mutations, we employed a PCR-cloning strategy previously used by our laboratories for mutation detection in clinical samples [23].”
MethodSelf-citationRexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 370
Soverini, S., Martinelli, G., Rosti, G., Bassi, S., Amabile, M., Poerio, A., Giannini, B., Trabacchi, E., Castagnetti, F., Testoni, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.531 · Cited by 374
Regales, L., Gong, Y., Shen, R., de Stanchina, E., Vivanco, I., Goel, A., Koutcher, J. A., Spassova, M., Ouerfelli, O., Mellinghoff, I. K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38746 · Cited by 368
Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, T., Adli, M., Hricik, T., Liu, F., Saunders, L. M., Mullally, A., Abdel-Wahab, O., et al. (2012) · Nature · doi:10.1038/nature11303 · Cited by 370
“…of targeted therapies has improved outcomes for patients with kinase-mutant malignancies 8–11 however acquired resistance due to mutations in the target kinase 12–14 or in other pathways that render cancer cells insensitive to kinase inhibitor therapy 15–18 remain important clinical concerns.”
BackgroundMolecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
Gambacorti-Passerini, C. B., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R., & Scapozza, L. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)00979-3 · Cited by 373
Imatinib as a Paradigm of Targeted Therapies
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91001-9 · Cited by 370
“Using this assay, it has been determined that the majority of patients who respond to imatinib and then relapse have reactivation of the BCR-ABL tyrosine kinase.(23) In these studies, greater than 50% and perhaps as many as 90% of patients have BCR-ABL point mutations in at least 13 different amino acids scattered thr…”
MethodMolecular Genetics of Acute Lymphoblastic Leukemia
Armstrong, S. A., & Look, A. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.047 · Cited by 362
“These early trials combining imatinib and chemotherapy are of significant interest; it is likely that other kinase inhibitors currently in development forboth leukemias andothercancers alsowill need to be combined with either chemotherapy or other targeted therapy because resistance to single-kinase inhibitors is beco…”
BackgroundSpecific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
Deininger, M. W. N., & Druker, B. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.4 · Cited by 365
“However, fluorescence-in situ hybridization (FISH), used to detect the BCR-ABL translocation, has become an important complementary method (Fig.”
BackgroundInfluentialOttmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R. A., Rege-Cambrin, G., Radich, J., Hochhaus, A., Apanovitch, A. M., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073528 · Cited by 366
“Median duration of ALL, mo (range) 20 (3-97)”
BackgroundJiang, X., Zhao, Y., Smith, C., Gasparetto, M., Turhan, A., Eaves, A., & Eaves, C. (2007) · Leukemia · doi:10.1038/sj.leu.2404609 · Cited by 359
Critical role for Gab2 in transformation by BCR/ABL
Sattler, M., Mohi, M. G., Pride, Y. B., Quinnan, L. R., Malouf, N. A., Podar, K., Gesbert, F., Iwasaki, H., Li, S., Van Etten, R. A., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00074-0 · Cited by 364
“Coloniesal., 2001; Gorre et al., 2001; Hochhaus et al., 2001).”
BackgroundTen things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
“These mutations include the Thr-gatekeeper of BCR–ABL1 (T315I) (Gorre et al., 2001; Sawyers, 2004; Fabbro et al., 2005), KIT (T670I) (Heinrich et al., 2003; Fletcher and Rubin, 2007), platelet-derived growth factor receptor-α (PDGFRα) (T674I) (Cools et al., 2003), PDGFRβ (T681I) (Daub et al., 2004) and Src (proto-onco…”
BackgroundInfluentialGuilhot, F., Apperley, J., Kim, D.-W., Bullorsky, E. O., Baccarani, M., Roboz, G. J., Amadori, S., de Souza, C. A., Lipton, J. H., Hochhaus, A., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046839 · Cited by 371
“(range) 165 (8-3580) 165 (8-3580) 166 (54-1463) Platelet count below 100 000/mm3, no.”
Zabriskie, M. S., Eide, C. A., Tantravahi, S. K., Vellore, N. A., Estrada, J., Nicolini, F. E., Khoury, H. J., Larson, R. A., Konopleva, M., Cortes, J. E., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.006 · Cited by 363
“Each position has been implicated in resistance to one or more TKIs: imatinib (Bradeen et al., 2006; Gorre et al., 2001), nilotinib (Bradeen et al., 2006; Ray et al., 2007; Weisberg et al., 2005), dasatinib (Bradeen et al., 2006; Burgess et al., 2005; Shah et al., 2004), bosutinib (Redaelli et al.,…”
Evaluation of HIF-1 inhibitors as anticancer agents
Semenza, G. L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.006 · Cited by 363
Levy, D., Adamovich, Y., Reuven, N., & Shaul, Y. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.022 · Cited by 347
“This is due to specific inhibition of c-Abl by STI571, because a c-Abl T334I mutant that is refractory to STI571 ( Gorre et al., 2001 ) completely recovered Yap1 phosphorylation (Figure 2F).”
BackgroundCancer stem cells – old concepts, new insights
Vermeulen, L., Sprick, M. R., Kemper, K., Stassi, G., & Medema, J. P. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.20 · Cited by 352
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.005 · Cited by 361
“Discrete mutations in the gene targets of therapeutic inhibitors have been long-identified as a common mechanism of resistance to targeted therapies (Ellis and Hicklin, 2009; Gorre et al., 2001; Woyach et al., 2014).”
Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2571 · Cited by 349
“T790M is analogous to the ABL T315I and KIT T670I "gatekeeper" mutations observed in imatinib-resistant chronic myelogenous leukemia and GIST, respectively (22, 23).”
BackgroundDruker, B. J., O’Brien, S. G., Cortes, J., & Radich, J. (2002) · Hematology · doi:10.1182/asheducation-2002.1.111 · Cited by 62
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Gainor, J. F., & Shaw, A. T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2029 · Cited by 346
“Target gene amplification is another cause of acquired resistance that was first identified in CML.50,61,67,69,80 Gene amplification may shift the intracellular balance between kinase and TKI in favor of the kinase.”
BackgroundInfluential
Metadata
- Authors
- Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Department of Pathology, and
- Department of Medicine,
- Corresponding author
- Sawyers, Charles L.
- Venue
- Science
- Published
- 2001-08-03
- Volume
- 293
- Issue
- 5531
- Pages
- 876-880
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1999614615
- Cited by
- 3,104
- References
- 26
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 45 · 2023: 64 · 2022: 44 · 2021: 60 · 2020: 71 · 2019: 76 · 2018: 68 · 2017: 84 · 2016: 96 · 2015: 106 · 2014: 141 · 2013: 169 · 2012: 162
- FWCI
- 85.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM-07185, T32GM007185)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- imatinib, BCR-ABL, chronic myeloid leukemia, drug resistance, Abl tyrosine kinase, BCR-ABL mutations, relapse
- MeSH terms
- Imatinib Mesylate, Amino Acid Sequence, Antineoplastic Agents, Base Sequence, Benzamides, Blast Crisis, Cell Line, Gene Amplification, Humans, Hydrogen Bonding, Molecular Sequence Data, Philadelphia Chromosome, Phosphorylation, Piperazines, Proto-Oncogene Proteins, Pyrimidines, Recurrence, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Genes, abl, Proto-Oncogene Proteins c-abl, Point Mutation, Protein Structure, Tertiary, Drug Resistance, Neoplasm, Amino Acid Substitution, Proto-Oncogene Proteins c-crk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.